Overview

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects

Status:
Completed

Trial end date:
2018-05-15

Target enrollment:

Participant gender:

Summary

This Phase 1 open label study is being conducted to directly characterize the pharmacokinetic (PK) profiles of seladelpar following administration of a single oral dose in subjects with varying degrees of hepatic impairment (HI) compared to healthy matched control subjects with normal hepatic function.

Phase:

Phase 1

Details

Lead Sponsor:

CymaBay Therapeutics, Inc.

Treatments:

Seladelpar